Drug stocks give FTSE a shot in the arm
The FTSE 100 is off to a good start to the week with gains of 12.5 points, or 0.23%, to 5,544.1, with drug stocks leading the advance in response to news a US judge has upheld key patents on Pfizer's Lipitor cholesterol drug.
AstraZeneca, which makes the Crestor cholesterol treatment, has risen 65p, or 2.37%, to 2,812p, while GlaxoSmithKline has gained 30p, or 2.05%, to 1,490p, as the US ruling handed Pfizer patent protection...
More on Investment
D2C investment platform users rise to all-time high in Q1
Customer numbers rise an average 3.1% across all providers
Neil Birrell: Negative interest rates have arrived in the UK
Base rate 0.1%
Schroders Personal Wealth hires Morningstar's Brunt to head manager research
Quilter's Jennifer Christian joins as investment specialist
Investors pull £325m from Premier Miton's multi-asset funds
Due to Covid-19
Negative interest rate debate becomes 'very real' as UK inflation drops to 0.8%
Lowest CPI reading since August 2016
More news
'Retirement income advice is the biggest problem in the adviser market' - Rory Percival
As important as DB transfers
D2C investment platform users rise to all-time high in Q1
Customer numbers rise an average 3.1% across all providers
Is it time to review the risks of DB transfer advice?
It’s The Pro Adviser Podcast
Advisers can defer CPD this year in 'exceptional circumstances' - FCA
Defer to 2021/2022